undamentalytics Newsletter
Sign in

Xeris Biopharma Holdings, Inc. insider trading

Every open-market purchase and sale by Xeris Biopharma Holdings, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $0 0 trades by 0 insiders Insider sales, 5 years $5.4M 32 trades by 9 insiders 3 months later: median +19.5% (+17.0% vs S&P 500)

No insider has bought shares on the open market in five years.

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Xeris Biopharma Holdings, Inc.’s insiders pay?

From November 12, 2021 to December 19, 2025, 10 insiders reported 15 open-market purchases and 5 sales not made under a pre-set plan in Xeris Biopharma Holdings, Inc. After sales, the shares moved −11.0% against the index over 12 months (a negative figure means selling was the right call).

InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Edick Paul R See Remarks 5 — — 0 — August 9, 2023
Schmid John P. Director 3 — — 0 — August 13, 2024
Johnson John Director 0 — — 2 −1.6% (1) December 19, 2025
Pieper Steven See Remarks 2 — — 0 — November 21, 2023
Shannon John Patrick Jr See Remarks 2 — — 0 — November 17, 2023
Sherman Jeffrey W Director 1 — — 1 −12.5% (1) August 29, 2025
Halkuff Dawn Director 0 — — 1 −4.4% (1) August 13, 2025
Hecht Beth See Remarks 0 — — 1 −25.4% (1) March 21, 2025
Mcculloch Kevin See Remarks 1 — — 0 — June 16, 2025
Persky Marla Director 1 — — 0 — November 15, 2023

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Xeris Biopharma Holdings, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Xeris Biopharma Holdings, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 1 selling crowd, −24.7%. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
September 30, 20253 selling−13.6%−24.7%−2.3%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Xeris Biopharma Holdings, Inc. · Funds · Politicians